semaglutide mn Minnesota doctor says FDA weight-loss drug cutoff is 'devastating' for patients Semaglutide Weight Loss Injections &

Natural GLP-1 Booster for Healthy Weight Management

GLP-1 medications are reshaping how America eats

- Avexitide is a novel, first-in-class GLP-1 receptor antagonist with the potential to treat hyperinsulinemic hypoglycemia - FDA Breakthrough Therapy Designation granted for avexitide for post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism - Acquisition builds on Amylyx endocrine and neuroscience expertise and aligns with pipeline focus of delivering important potential treatment options to communities with high unmet needs - Phase 3 program for avexitide in PBH expected to begin in Q1 2025, with data readout anticipated in 2026

Physician-supervised GLP-1 weight loss injections in Columbus, GA

Manufactured in the USA under UL Solutions GMP certification (valid until November 12, 2028)